Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arbutus Biopharma Corporation

Latest From Arbutus Biopharma Corporation

Abecma Or Bust: 2seventy Sells Final Research Program To Novo

2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.

Deals Research & Development

China Biotech Podcast: Going Global Trends, Rare Disease Drug Development

Guest speaker Professor Guangzuo Luo joins Brian Yang and Dexter Yang to discuss orphan drug development and going global trends for Chinese bioventures, along with the latest business moves from Shanghai Fosun and Jiangsu Hengrui.

China Business Strategies

Fresenius Is Latest To File Denosumab With US FDA

With activity around denosumab biosimilars continuing to heat up, Fresenius Kabi has announced US FDA acceptance of its filing, while China’s Henlius says the EMA is reviewing its own biosimilar submission.

Biosimilars United States

Fosun To Fully Acquire Henlius In Go-Global Push?

Parent Fosun and biosimilars arm Henlius halt share trading on the same day, sparking speculation of a buy-out deal that would assist the Chinese firms' globalization push.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Liposomes
    • Nanotechnology, Chips, etc.
  • Other Names / Subsidiaries
    • Genevant Sciences
    • Inex Pharmaceuticals Corporation
    • OnCore Biopharma, Inc, (Enantigen Therapeutics, Inc.)
    • Tekmira Pharmaceuticals Corporation (TKMR)
    • Protiva Biotherapeutics Inc.